

## ACTION

# Buy

## ITC (ITC.BO)

Return Potential: 16%


Equity Research

### High FCF growth, robust pricing power; raise to Buy

#### Source of opportunity

ITC has corrected by 8% over the last 30 days, underperforming the sector by 4% and now trades 1SD below the sector aggregate on a 12-month forward P/E. We believe the correction has been led by broader market weakness and concerns on taxation given fiscal challenges. We view this as an entry opportunity since ITC enjoys tremendous pricing power which will help mitigate higher taxes and is not fully factored into the present stock price. We raise ITC to Buy with a revised 12-month target price of Rs232 (from Rs201) as we believe ITC is well protected in the current uncertain environment given improving cash returns and visibility of margins.

#### Investment Profile



#### Catalyst

We expect ITC to continue to show robust yoy volume growth of 8+% in 2HFY12 as seen in 1Q-2QFY12. ITC enjoys strong pricing power, with key brands seeing retail price increases at a 9% CAGR over the past 5 years against inflation of 6.5%. For FYTD ITC has increased prices by 3% (6% yoy) allowing it leverage to balance increases in taxation. We believe ITC is least affected by input cost inflation or INR depreciation in our coverage.

#### Valuation

ITC trades at FY13E P/E of 20.2X compared with 25.1X for the sector. We raise FY12E-14E EPS by 1%-7% to factor in higher volumes for the cigarette business. Our 12m TP is set at 24X FY13E EPS, backed by Director's Cut analysis. We raise our target multiple from 22X to factor in (1) increased cash generation and higher dividend payout ratio, (2) increased pricing power owing to strong brand portfolio and limited competition, and (3) improvement in CROCI to 50% in FY13E from 39% in FY11. We expect ITC cash surplus to increase to Rs61 bn in FY13E from Rs39 bn in FY11.

#### Key risks

- (1) Increase in VAT rates over 20% by states and significant excise hikes,
- (2) Stringent anti-smoking legislation, (3) Sustained FMCG losses.

#### INVESTMENT LIST MEMBERSHIP

Asia Pacific Buy List

#### Coverage View: Neutral


**Puneet Jain**  
+91(22)6616-9046 puneet.jain@gs.com Goldman Sachs India SPL

**Aditya Soman**  
+91(22)6616-9345 aditya.soman@gs.com Goldman Sachs India SPL

Key data	Current
Price (Rs)	199.65
12 month price target (Rs)	232.00
Market cap (Rs mn / US\$ mn)	1,544,921.4 / 29,026.2
Foreign ownership (%)	--

	3/11	3/12E	3/13E	3/14E
EPS (Rs) New	6.49	7.86	9.68	11.22
EPS revision (%)	0.0	1.2	5.7	7.3
EPS growth (%)	22.2	21.2	23.1	16.0
EPS (dil) (Rs) New	6.49	7.86	9.68	11.22
P/E (X)	30.8	25.4	20.6	17.8
P/B (X)	9.7	8.6	7.5	6.6
EV/EBITDA (X)	16.1	16.9	13.4	11.3
Dividend yield (%)	2.2	2.3	2.8	3.3
ROE (%)	33.2	35.9	39.0	39.7
CROCI (%)	33.9	44.8	50.5	54.0

#### Price performance chart



Share price performance (%)	3 month	6 month	12 month
Absolute	0.3	3.0	18.6
Rel. to India BSE30 Sensex	5.5	18.8	47.9

Source: Company data, Goldman Sachs Research estimates, FactSet. Price as of 12/14/2011 close.

Goldman Sachs does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For Reg AC certification and other important disclosures, see the Disclosure Appendix, or go to [www.gs.com/research/hedge.html](http://www.gs.com/research/hedge.html). Analysts employed by non-US affiliates are not registered/qualified as research analysts with FINRA in the U.S.

# ITC: Summary Financials

Profit model (Rs mn)	3/11	3/12E	3/13E	3/14E	Balance sheet (Rs mn)	3/11	3/12E	3/13E	3/14E
<b>Total revenue</b>	<b>211,675.8</b>	<b>250,083.8</b>	<b>299,670.0</b>	<b>344,673.4</b>	Cash & equivalents	22,432.4	33,450.5	53,071.9	74,249.5
Cost of goods sold	(108,992.5)	(125,647.7)	(148,930.9)	(169,604.6)	Accounts receivable	9,076.2	11,305.2	13,136.2	15,109.0
SG&A	(37,708.8)	(45,267.2)	(51,252.5)	(58,287.0)	Inventory	52,675.3	58,443.5	69,095.1	78,394.4
R&D	--	--	--	--	Other current assets	17,655.8	18,538.6	19,465.5	20,438.8
Other operating profit/(expense)	3,032.4	3,270.9	3,397.0	3,529.3	<b>Total current assets</b>	<b>101,839.7</b>	<b>121,737.7</b>	<b>154,768.7</b>	<b>188,191.6</b>
<b>EBITDA</b>	<b>74,566.7</b>	<b>89,569.6</b>	<b>111,295.3</b>	<b>130,017.3</b>	Net PP&E	96,784.7	107,329.4	120,673.1	135,620.6
Depreciation & amortization	(6,559.9)	(7,129.8)	(8,411.8)	(9,706.2)	Net intangibles	0.0	0.0	0.0	0.0
<b>EBIT</b>	<b>68,006.8</b>	<b>82,439.8</b>	<b>102,883.5</b>	<b>120,311.1</b>	Total investments	55,546.6	53,491.2	51,435.8	49,380.4
Interest income	1,068.0	670.0	703.5	738.7	Other long-term assets	0.0	0.0	0.0	0.0
Interest expense	(481.3)	(505.4)	(530.6)	(557.2)	<b>Total assets</b>	<b>254,171.0</b>	<b>282,558.3</b>	<b>326,877.7</b>	<b>373,192.6</b>
Income/(loss) from uncons. subs.	0.0	0.0	0.0	0.0	Accounts payable	43,821.3	51,387.1	61,576.0	70,823.3
Others	4,088.0	5,993.5	5,808.5	5,623.5	Short-term debt	0.0	0.0	0.0	0.0
<b>Pretax profits</b>	<b>72,681.5</b>	<b>88,598.0</b>	<b>108,864.9</b>	<b>126,116.2</b>	Other current liabilities	41,806.5	42,524.5	51,577.6	60,630.7
Income tax	(22,805.5)	(27,755.3)	(33,995.6)	(39,256.6)	<b>Total current liabilities</b>	<b>85,627.8</b>	<b>93,911.6</b>	<b>113,153.6</b>	<b>131,454.0</b>
Minorities	0.0	0.0	0.0	0.0	Long-term debt	992.0	992.0	992.0	992.0
<b>Net income pre-preferred dividends</b>	<b>49,876.0</b>	<b>60,842.6</b>	<b>74,869.4</b>	<b>86,859.7</b>	Other long-term liabilities	8,018.5	8,018.5	8,018.5	8,018.5
Preferred dividends	0.0	0.0	0.0	0.0	Total long-term liabilities	9,010.5	9,010.5	9,010.5	9,010.5
<b>Net income (pre-exceptionals)</b>	<b>49,876.0</b>	<b>60,842.6</b>	<b>74,869.4</b>	<b>86,859.7</b>	<b>Total liabilities</b>	<b>94,638.3</b>	<b>102,922.1</b>	<b>122,164.1</b>	<b>140,464.5</b>
Post-tax exceptionals	0.0	0.0	0.0	0.0	<b>Preferred shares</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>	<b>0.0</b>
<b>Net income</b>	<b>49,876.0</b>	<b>60,842.6</b>	<b>74,869.4</b>	<b>86,859.7</b>	<b>Total common equity</b>	<b>159,532.7</b>	<b>179,636.2</b>	<b>204,713.5</b>	<b>232,728.1</b>
EPS (basic, pre-exception) (Rs)	6.49	7.86	9.68	11.22	Minority interest	0.0	0.0	0.0	0.0
EPS (basic, post-exception) (Rs)	6.49	7.86	9.68	11.22	<b>Total liabilities &amp; equity</b>	<b>254,171.0</b>	<b>282,558.3</b>	<b>326,877.7</b>	<b>373,192.6</b>
EPS (diluted, post-exception) (Rs)	6.49	7.86	9.68	11.22	<b>BVPS (Rs)</b>	<b>20.62</b>	<b>23.21</b>	<b>26.46</b>	<b>30.08</b>
DPS (Rs)	4.48	4.50	5.50	6.50					
Dividend payout ratio (%)	69.0	57.2	56.8	57.9					
Free cash flow yield (%)	3.4	3.0	3.6	4.3					
Growth & margins (%)	3/11	3/12E	3/13E	3/14E	Ratios	3/11	3/12E	3/13E	3/14E
Sales growth	16.6	18.1	19.8	15.0	CROCI (%)	33.9	44.8	50.5	54.0
EBITDA growth	18.3	20.1	24.3	16.8	ROE (%)	33.2	35.9	39.0	39.7
EBIT growth	19.5	21.2	24.8	16.9	ROA (%)	20.6	22.7	24.6	24.8
Net income growth	22.8	22.0	23.1	16.0	ROACE (%)	36.8	42.6	49.9	55.6
EPS growth	20.9	21.2	23.1	16.0	Inventory days	164.4	161.4	156.3	158.7
Gross margin	48.5	49.8	50.3	50.8	Receivables days	15.2	14.9	14.9	15.0
EBITDA margin	35.2	35.8	37.1	37.7	Payable days	131.0	138.3	138.4	142.5
EBIT margin	32.1	33.0	34.3	34.9	Net debt/equity (%)	(13.4)	(18.1)	(25.4)	(31.5)
					Interest cover - EBIT (X)	NM	NM	NM	NM
Cash flow statement (Rs mn)	3/11	3/12E	3/13E	3/14E	Valuation	3/11	3/12E	3/13E	3/14E
Net income pre-preferred dividends	49,876.0	60,842.6	74,869.4	86,859.7	P/E (analyst) (X)	30.8	25.4	20.6	17.8
D&A add-back	6,559.9	7,129.8	8,411.8	9,706.2	P/B (X)	9.7	8.6	7.5	6.6
Minorities interests add-back	0.0	0.0	0.0	0.0	EV/EBITDA (X)	16.1	16.9	13.4	11.3
Net (inc)/dec working capital	52.0	(1,314.1)	(3,220.6)	(2,998.1)	EV/GCI (X)	8.7	9.9	9.0	8.1
Other operating cash flow	(19.0)	3,318.9	3,236.7	3,154.5	Dividend yield (%)	2.2	2.3	2.8	3.3
<b>Cash flow from operations</b>	<b>53,998.3</b>	<b>63,983.7</b>	<b>77,488.8</b>	<b>91,098.7</b>					
Capital expenditures	(12,814.6)	(17,674.5)	(21,755.6)	(24,653.6)					
Acquisitions	0.0	0.0	0.0	0.0					
Divestitures	0.0	0.0	0.0	0.0					
Others	5,550.0	4,730.0	4,627.2	4,524.4					
<b>Cash flow from investments</b>	<b>(7,264.6)</b>	<b>(12,944.5)</b>	<b>(17,128.4)</b>	<b>(20,129.2)</b>					
Dividends paid (common & pref)	(44,517.3)	(40,020.9)	(40,738.9)	(49,792.0)					
Inc/(dec) in debt	(104.5)	0.0	0.0	0.0					
Common stock issuance (repurchase)	9,038.2	0.0	0.0	0.0					
Other financing cash flows	19.4	0.0	0.0	0.0					
<b>Cash flow from financing</b>	<b>(35,564.2)</b>	<b>(40,020.9)</b>	<b>(40,738.9)</b>	<b>(49,792.0)</b>					
<b>Total cash flow</b>	<b>11,169.5</b>	<b>11,018.3</b>	<b>19,621.4</b>	<b>21,177.5</b>					

Note: Last actual year may include reported and estimated data.

Source: Company data, Goldman Sachs Research estimates.

## Analyst Contributors

### Puneet Jain

puneet.jain@gs.com

### Aditya Soman

aditya.soman@gs.com

## Buy for cash generation, EBIT growth; Valuations offer upside

We raise ITC to Buy with a revised 12-month target price of Rs232 (from Rs201) as we believe the current valuations do not fully capture improving cash returns (CROCI set to increase to 50% in FY13E from 39% in FY11). In our consumer coverage, only ITC has seen margin expansion for the last two years. ITC now trades 1SD below the sector aggregate on a 12-month forward P/E following 5% underperformance compared with the sector average over the last 60 days.

### Robust cash generation leading to higher dividend payouts

ITC has seen a sharp jump in post tax cash from operations (before working capital changes) to Rs53bn in FY11 as compared with Rs32bn in FY08 given good growth across various businesses. However incremental capital requirements decreased due to lesser investments required in FMCG and paper businesses. This has led to surplus cash post capital employed in the business increasing to Rs40bn in FY11 as compared with Rs5bn in FY08. As cash generation increased ITC has raised dividend payout ratio to 94% and 69% in FY10 and FY11, respectively, as compared with 42%-45% in the previous 4 years (Exhibit 1).

#### Exhibit 1: Surplus cash generation has increased to Rs40bn in FY11 as compared with Rs4.6bn in FY08

Cash from operations and incremental capital employed (Rs mn)


Rs mn	FY 2006	FY 2007	FY 2008	FY 2009	FY 2010	FY 2011	FY 2012E	FY 2013E	FY 2014E
Cash from operations (post tax but before WC changes)	24,641	28,084	31,545	35,529	43,156	52,590	65,133	80,536	93,915
Incremental capital employed	(12,275)	(25,134)	(26,897)	(19,447)	(7,923)	(12,688)	(15,961)	(19,957)	(22,765)
FMCG - Cigarettes	(3,267)	(6,388)	(4,519)	(9,195)	(525)	(2,935)	(4,159)	(5,438)	(6,761)
FMCG - Others	(2,402)	(4,931)	(9,066)	(3,265)	3,386	(3,240)	(2,492)	(3,136)	(3,948)
Hotels	(327)	(1,538)	(4,633)	(3,911)	(3,463)	(3,563)	(4,167)	(4,968)	(5,869)
Agri Business	(3,511)	(4,546)	(275)	3,917	(5,753)	(48)	(1,116)	(1,686)	(1,949)
Paperboards, paper and packaging	(2,768)	(7,732)	(8,404)	(6,993)	(1,568)	(2,902)	(4,028)	(4,729)	(4,239)
Surplus	12,366	2,950	4,647	16,082	35,233	39,902	49,172	60,580	71,150
Rolling 3 year average			6,655	7,893	18,654	30,406	41,436	49,885	60,301
yoy				19%	136%	63%	36%	20%	21%
Dividend	9,951	11,663	13,190	13,965	38,182	34,435	34,822	42,560	50,298
Dividend payout ratio	45%	43%	42%	43%	94%	69%	57%	57%	58%

Source: Company data, Goldman Sachs Research.

### Tobacco business-high pricing power aiding returns, growth

We expect this business to continue to generate CROCI of 100+% given high pricing power owing to strong brand portfolio and limited competition. We expect EBIT CAGR of 18% between FY11-FY14E, inline with the recent past. ITC has consistently outsold other cigarette companies over the last few years despite taking up prices at a 9% CAGR over the past 5 years. This points to significant pricing power enjoyed by ITC brands (Exhibit 3). The cigarette division has seen EBIT margins expand from 23.9% of net sales in FY06 to 29.1% in FY11 and we are forecasting cigarette EBIT to expand to 31.4% in FY13E.

**Exhibit 2: Volume growth has surprised in 1HFY12**  
Quarterly cigarette volume growth




Source: Company data, Goldman Sachs Research.

**Exhibit 3: Pricing has grown at a 9% CAGR since 2005**  
Cigarette prices (Rs/stick) and 2005-11 CAGR

Rs/stick	Gold Flake Kings	Navy Cut	Classic
2005	3.0	2.5	3.3
2011	4.8	4.4	5.5
<b>2005-11 CAGR</b>	<b>8.5%</b>	<b>9.9%</b>	<b>9.2%</b>
2005-11 Inflation CAGR	6.5%	6.5%	6.5%
<b>2005-11 Real price growth</b>	<b>2.0%</b>	<b>3.4%</b>	<b>2.7%</b>


Source: Goldman Sachs Research.

**Exhibit 4: Cigarette EBIT growth has shown stability**  
Cigarettes – EBIT growth and tax growth



Source: Company data, Goldman Sachs Research.


**Exhibit 5: Cigarette CROCI still on the upswing**  
Cigarette division CROCI trend



Source: Goldman Sachs Research estimates.


**FMCG business.** On the back on continued investments, ITC has seen FMCG sales growing at a CAGR of 21% between FY2008-11. As of FY2011, ITC has gross cash invested (GCI) of Rs25 bn and has also funded EBITDA losses of Rs21.4 bn. Based on better scale and brand stability, we forecast the business to turn profitable in FY13E. We expect scale benefits to accrue from market share gains (Personal care-soaps/ fairness creams, snacks - chips, biscuits and flour) as well as spreading of A&P and sales expenses over a larger base.

**Exhibit 6: We expect break-even in FY13E for FMCG**  
FMCG division – Sales and EBIT margins



Source: Company data, Goldman Sachs Research.

**Exhibit 7: Returns catching up with capital employed**  
FMCG division – CROCI and Capital Employed



Source: Company data, Goldman Sachs Research.


## ITC is least affected by raw material inflation, INR depreciation

The three largest constituents of raw material consumption are unmanufactured Tobacco, pulp and wheat amounting to more than 40% of raw material cost. Latest auction data indicate a marginal decline in tobacco prices yoy (Exhibit 8).

Among our coverage universe, ITC is least affected by INR depreciation as it is a net forex earning company. During FY2011, ITC and its subsidiaries earned Rs31.2 bn in foreign exchange driven by exports of agri commodities and hotel business while direct expenditure amounted to Rs12.5 bn. Thus it earned net foreign exchange of Rs19 bn.

**Exhibit 8: Tobacco prices have declined since 2008**

Karnataka auction - Tobacco prices by grade



Source: Indian Tobacco Board, Goldman Sachs Research.

**Exhibit 9: ITC least affected by raw material inflation**

GS Consumer coverage across key metrics

	Key raw material inflation		Pricing power in key categories		Competitive intensity in key categories		FY13E P/E	FY13E CROCI	FY11-13E CROCI Trend	FY11-14E REV CAGR	FY11-14E PAT CAGR
	Current	Trend	Current	Trend	Current	Trend					
COLG.BO	High	Increasing	Medium	Stable	Medium	Increasing	25.7X	126%	Decreasing	16.0%	15.1%
DABU.BO	Medium	Increasing	Medium	Stable	Medium	Increasing	21.1X	28%	Increasing	20.0%	18.9%
HLL.BO	High	Increasing	Medium	Decreasing	High	Increasing	28.2X	142%	Decreasing	14.2%	12.5%
ITC.BO	Low	Decreasing	High	Increasing	Low	Stable	20.2X	50%	Increasing	17.6%	20.3%
MRCO.BO	Medium	Increasing	High	Stable	Medium	Stable	21.8X	30%	Increasing	23.6%	20.0%
NEST.BO	Medium	Decreasing	High	Decreasing	Medium	Increasing	33.6X	54%	Decreasing	20.0%	19.7%

Source: Goldman Sachs Research estimates.

ITC is amongst the few companies with 1st quartile CROCI that we expect to show further improvement in FY11-13. Other companies we expect to show improvement are primarily in commodities and automobiles. Within the FMCG universe, we expect ITC to show the largest improvement.

**Exhibit 10: ITC has top quartile EBIT margins with significant expansion potential**

EBIT margins and margin improvement – Top quartile companies under India coverage

	Top quartile EBIT margins	Margin improvement (bps)
	FY2011	FY2011-FY2013E
GSPT.BO	80.1%	13
CAIL.BO	69.7%	(1,472)
JYPE.BO	64.9%	(2,312)
PGRD.BO	57.4%	266
PHOE.BO	55.6%	(105)
OEBO.BO	55.6%	381
SESA.BO	55.5%	(1,168)
HDIL.BO	55.1%	(1,209)
SUTV.BO	54.5%	(124)
HZNC.BO	51.9%	249
ADAN.BO	48.3%	(1,416)
NHPC.BO	47.9%	535
JNSP.BO	40.0%	(882)
KSKE.BO	37.9%	(199)
OILI.BO	37.1%	324
IRBI.BO	36.0%	80
GODR.BO	35.3%	(809)
DLF.BO	33.1%	613
ITC.BO	32.1%	220
JSWE.BO	30.2%	(123)
INFY.BO	29.5%	(97)
COAL.BO	28.7%	219
UNTE.BO	28.0%	(163)
TCS.BO	28.0%	(120)
ILFT.BO	27.0%	(147)
BSSL.BO	25.8%	(298)
ONGC.BO	25.5%	613
STRL.BO	24.3%	(153)

Source: Company data, Goldman Sachs Research estimates.

**Exhibit 11: Exhibit 10: ITC has top quartile CROCI and we forecast CROCI to increase more than 600bp**

CROCI and CROCI increase – Top quartile companies under India coverage

	Top quartile CROCI	CROCI increase (bps)
	FY2013E	FY2011-FY2013E
HLL.BO	142%	(3,267)
COLG.BO	126%	(2,819)
BAJA.BO	111%	3,859
NEST.BO	54%	(594)
ITC.BO	50%	1,170
HZNC.BO	48%	(148)
INFY.BO	46%	(337)
TCS.BO	45%	(458)
COAL.BO	45%	1,435
HROM.BO	38%	1,555
DSTV.BO	32%	603
SUTV.BO	31%	(794)
OEBO.BO	31%	882
MRCO.BO	30%	(126)
BOSH.BO	29%	184
HVEL.BO	28%	271
DABU.BO	28%	(859)
BHEL.BO	26%	(1,345)
CAIL.BO	25%	1,030
EXID.BO	25%	108
HCLT.BO	23%	154
CUMM.BO	22%	(466)
WIPR.BO	20%	(388)
CROM.BO	20%	(599)
IRBI.BO	20%	(203)
MBFL.BO	20%	(2,193)
THMX.BO	19%	(1,270)
JYPE.BO	19%	(445)

Source: Company data, Goldman Sachs Research estimates.

## Improving cash margins and asset turns driving returns

We believe ITC's CROCI will improve to 50% in FY13E, driven not only by the cigarette business but also increasing contributions from other businesses like FMCG-Others, Paper and Agri. Over the past few years ITC has invested surplus cash generated by the cigarette business into building better brands in other businesses. Several of these brands are now beginning to show robust revenue growth leading to better asset turns. The businesses are also increasingly profitable leading to an expansion in cash margins.

The cigarette business continues to deliver very robust returns and generates substantial cash flows. We expect the cigarette business to throw up an average DACF of Rs59bn between FY12E-14E, with CROCI expanding from 101% in FY11 to 124% in FY14E. This gives us a fair degree of confidence in our CROCI estimates.

### Exhibit 12: ITC is the only company in our India consumer coverage to have seen margin expansion in FY09-FY10

Change in EBIT margins (bps)


EBIT margin Δ (bps)	FY2005	FY2006	FY2007	FY2008	FY2009	FY2010	FY2011	FY2012E	FY2013E	FY2014E
COLG.BO	203	(88)	(111)	372	22	583	(127)	(102)	20	20
DABU.BO	579	224	154	56	(71)	179	(8)	(90)	39	9
HLL.BO	(533)	(140)	72	122	(66)	10	(187)	99	43	(8)
ITC.BO	1	(182)	(131)	(15)	(94)	205	77	84	137	57
MRCO.BO	32	145	161	100	(8)	61	(13)	(102)	(40)	20
NEST.BO	(131)	142	(176)	92	(24)	1	44	24	(13)	37
Coverage	(165)	(38)	14	59	(87)	144	(28)	47	81	26
Coverage ex ITC	(320)	(42)	35	125	(50)	74	(102)	30	26	11

Note: Blue highlight indicates substantial margin expansion, grey high light indicates significant contraction.

Source: Company data, Goldman Sachs Research estimates.

### Exhibit 13: Cigarette division still drives CROCI


CROCI trend



Source: Company data, Goldman Sachs Research estimates.

### Exhibit 14: .. returns also improving for FMCG business


CROCI trend – divisions expect cigarettes



Source: Company data, Goldman Sachs Research estimates.



**Exhibit 15: CROCI driven by asset turns and margins**  
CROCI, Asset turns (X) and cash margins



Source: Company data, Goldman Sachs Research estimates.

## Valuations offer upside from current levels

ITC trades at an FY13E P/E of 20.2X as compared with 25.1X for the sector. We increased our FY12E-14E EPS estimates by 1%-7% to factor in higher volumes and pricing for the cigarette business. Our 12-month target price is set at 24X FY13E EPS of Rs9.68 and is backed by Director's Cut analysis. We raise our target multiple from 22X to factor in (1) ITC's increased cash generation and higher dividend payout ratio, (2) increased pricing power owing to strong brand portfolio and limited competition, and (3) improvement in CROCI to 50% in FY13E from 39% in FY11. ITC's DCF increased from Rs36bn in FY09 to Rs54bn in FY11 and we forecast Rs81bn in FY13E. Increased dividend payout also suggests that the company is generating cash and repaying equity investors. Our Director's Cut and SOTP analysis also suggest valuation similar valuation (Exhibit 16 & 17).

**Exhibit 16: Our TP is broadly in-line with DC valuation**  
Director's Cut Valuation

DC Valuation	
DC Sector multiple	2.3X
FY2013E CROCI / WACC	4.6X
<b>Implied value EV/GCI</b>	<b>10.4X</b>
FY2013E GCI Rs mn	166,235
<b>Implied EV Rs mn</b>	<b>1,728,184</b>
FY2013E Net Debt Rs mn	(52,080)
<b>Implied Mkt. Cap. Rs mn</b>	<b>1,780,264</b>
FY2013E Shares out. mn	7,738
<b>DC Implied Valuation Rs / share</b>	<b>230</b>

Source: Goldman Sachs Research estimates.


**Exhibit 17: Also in-line with a SOTP based valuation**  
SOTP valuation

SOTP Value	Rs mn	Rs/share
<b>EV</b>	<b>1,687,010</b>	<b>218</b>
FMCG Cigarettes (24X FY13E EPS)	1,359,145	176
FMCG - Others (1.5X FY13E Sales)	102,326	13
Hotels (12X FY13E EBITDA)	59,100	8
Agri (6X FY13E EBITDA)	48,995	6
Paper (8X FY13E EBITDA)	117,444	15
Net debt - FY13E	-103,516	(13)
<b>Equity Value</b>	<b>1,790,526</b>	<b>231</b>
No of shares (mn)	7,738	

Source: Goldman Sachs Research estimates.




**Exhibit 18: Trading below the line with increasing returns**  
FY13E EV/GCI vs FY13E CROCI/WACC




Source: Goldman Sachs Research estimates.

**Exhibit 19: ITC discount - 1SD below 5 year mean**  
12-month fwd P/E relative to India consumer coverage




Source: Datastream, Company data, Goldman Sachs Research estimates.

**Exhibit 20: ITC P/E does not capture growth potential**  
FY13E P/E and FY11-FY14E Net income CAGR



Source: Datastream, Company data, Goldman Sachs Research estimates.

**Exhibit 21: ITC has corrected recently**  
12-month fwd P/E



Source: Datastream, Company data, Goldman Sachs Research estimates.

## More than a cigarette company

ITC is India's leading cigarette company with more than 70% volume and value market share. ITC has 6 of the top 10 cigarette brands in India including the top three.

ITC also runs India's second largest chain of hotels under four brands - ITC Hotels, WelcomHotel, Fortune & WelcomHeritage


ITC's paper and paperboards business is India's largest with revenues >Rs8bn in FY11

ITC's agri business is India's largest in leaf tobacco trading and 2nd largest in agri commodities with farm linkages in 14 States covering Soya, Wheat, Marine products, Coffee etc.

ITC also has a consumer staples business with a focus on packaged food and personal care.

**Exhibit 22: ITC has more than 2/3 of the value market share in cigarettes**

ITC volume and value market share



Source: Company data, Goldman Sachs Research.

**Exhibit 23: Share of cigarettes in EBIT reducing as other businesses turn more profitable**

Sales and contribution (Rs mn)

Net sales (Rs mn)	FY 2007	FY 2008	FY 2009	FY 2010	FY 2011	FY 2012E	FY 2013E	FY 2014E
FMCG - Cigarettes	58,949	66,350	77,807	93,212	105,737	122,975	146,769	163,661
FMCG - Others	16,895	25,096	30,056	36,339	44,716	54,945	68,054	84,516
Hotels	9,058	10,121	9,355	8,507	10,008	11,351	13,493	15,899
Agri Business	35,013	38,684	38,460	38,621	47,480	56,398	66,502	75,789
Paperboards, paper and packaging	19,106	21,579	26,471	31,078	35,072	40,779	47,598	53,785
Eliminations	(17,378)	(22,355)	(26,029)	-	(31,337)	(36,364)	(42,745)	(48,976)
<b>Consolidated total</b>	<b>121,643</b>	<b>139,475</b>	<b>153,881</b>	<b>181,532</b>	<b>211,676</b>	<b>250,084</b>	<b>299,670</b>	<b>344,673</b>

Net sales Contribution	FY 2007	FY 2008	FY 2009	FY 2010	FY 2011	FY 2012E	FY 2013E	FY 2014E
FMCG - Cigarettes	48%	48%	51%	51%	50%	49%	49%	47%
FMCG - Others	14%	18%	20%	20%	21%	22%	23%	25%
Hotels	7%	7%	6%	5%	5%	5%	5%	5%
Agri Business	29%	28%	25%	21%	22%	23%	22%	22%
Paperboards, paper and packaging	16%	15%	17%	17%	17%	16%	16%	16%
Eliminations	-14%	-16%	-17%	-14%	-15%	-15%	-14%	-14%
<b>Consolidated total</b>	<b>100%</b>	<b>100%</b>	<b>101%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>

EBIT Contribution	FY 2007	FY 2008	FY 2009	FY 2010	FY 2011	FY 2012E	FY 2013E	FY 2014E
FMCG - Cigarettes	83%	84%	89%	83%	81%	80%	78%	78%
FMCG - Others	-5%	-6%	-10%	-6%	-4%	-3%	1%	1%
Hotels	9%	9%	7%	4%	4%	4%	4%	3%
Agri Business	3%	3%	5%	7%	8%	8%	7%	7%
Paperboards, paper and packaging	11%	10%	11%	12%	12%	11%	11%	11%
Eliminations	-1%	-1%	-2%	0%	0%	0%	0%	0%
<b>Consolidated total</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>	<b>100%</b>

EBIT Margin	FY 2007	FY 2008	FY 2009	FY 2010	FY 2011	FY 2012E	FY 2013E	FY 2014E
FMCG - Cigarettes	24.7%	26.3%	27.7%	28.6%	29.1%	30.6%	31.4%	32.4%
FMCG - Others	-12.0%	-10.5%	-16.0%	-9.6%	-6.6%	-4.0%	0.8%	2.0%
Hotels	35.6%	37.3%	31.0%	23.8%	24.7%	26.0%	26.0%	25.0%
Agri Business	3.5%	3.3%	6.7%	11.3%	11.9%	12.0%	11.8%	11.0%
Paperboards, paper and packaging	19.8%	19.2%	18.0%	21.2%	22.3%	23.0%	23.5%	23.5%
Eliminations	1.7%	1.5%	3.8%	0.0%	0.0%	0.0%	0.0%	0.0%
<b>Consolidated total</b>	<b>19.2%</b>	<b>19.6%</b>	<b>19.5%</b>	<b>23.1%</b>	<b>23.9%</b>	<b>25.1%</b>	<b>26.2%</b>	<b>26.5%</b>

Source: Company data, Goldman Sachs Research estimates.

# Disclosure Appendix

## Reg AC

We, Puneet Jain and Aditya Soman, hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

## Investment Profile

The Goldman Sachs Investment Profile provides investment context for a security by comparing key attributes of that security to its peer group and market. The four key attributes depicted are: growth, returns, multiple and volatility. Growth, returns and multiple are indexed based on composites of several methodologies to determine the stocks percentile ranking within the region's coverage universe.

The precise calculation of each metric may vary depending on the fiscal year, industry and region but the standard approach is as follows:

**Growth** is a composite of next year's estimate over current year's estimate, e.g. EPS, EBITDA, Revenue. **Return** is a year one prospective aggregate of various return on capital measures, e.g. CROCI, ROACE, and ROE. **Multiple** is a composite of one-year forward valuation ratios, e.g. P/E, dividend yield, EV/FCF, EV/EBITDA, EV/DACF, Price/Book. **Volatility** is measured as trailing twelve-month volatility adjusted for dividends.

## Quantum

Quantum is Goldman Sachs' proprietary database providing access to detailed financial statement histories, forecasts and ratios. It can be used for in-depth analysis of a single company, or to make comparisons between companies in different sectors and markets.

## GS SUSTAIN

GS SUSTAIN is a global investment strategy aimed at long-term, long-only performance with a low turnover of ideas. The GS SUSTAIN focus list includes leaders our analysis shows to be well positioned to deliver long term outperformance through sustained competitive advantage and superior returns on capital relative to their global industry peers. Leaders are identified based on quantifiable analysis of three aspects of corporate performance: cash return on cash invested, industry positioning and management quality (the effectiveness of companies' management of the environmental, social and governance issues facing their industry).

## Disclosures

### Coverage group(s) of stocks by primary analyst(s)

Puneet Jain: India Consumer, India Property. Aditya Soman: India Consumer.

India Consumer: Colgate Palmolive (India), Dabur India, Hindustan Unilever, ITC, Marico, Nestle India.

India Property: DLF, Godrej Properties, Housing Development & Infrastructure, Indiabulls Real Estate Limited, Jaypee Infratech, Oberoi Realty, Phoenix Mills, Prestige Estates Projects, Sobha Developers, Unitech.

### Company-specific regulatory disclosures

The following disclosures relate to relationships between The Goldman Sachs Group, Inc. (with its affiliates, "Goldman Sachs") and companies covered by the Global Investment Research Division of Goldman Sachs and referred to in this research.

There are no company-specific disclosures for: ITC (Rs199.65)


### Distribution of ratings/investment banking relationships

Goldman Sachs Investment Research global coverage universe

	Rating Distribution			Investment Banking Relationships		
	Buy	Hold	Sell	Buy	Hold	Sell
Global	31%	55%	14%	50%	43%	36%

As of October 1, 2011, Goldman Sachs Global Investment Research had investment ratings on 3,198 equity securities. Goldman Sachs assigns stocks as Buys and Sells on various regional Investment Lists; stocks not so assigned are deemed Neutral. Such assignments equate to Buy, Hold and Sell for the purposes of the above disclosure required by NASD/NYSE rules. See 'Ratings, Coverage groups and views and related definitions' below.

## Price target and rating history chart(s)



The price targets shown should be considered in the context of all prior published Goldman Sachs research, which may or may not have included price targets, as well as developments relating to the company, its industry and financial markets.

## Regulatory disclosures

### Disclosures required by United States laws and regulations

See company-specific regulatory disclosures above for any of the following disclosures required as to companies referred to in this report: manager or co-manager in a pending transaction; 1% or other ownership; compensation for certain services; types of client relationships; managed/co-managed public offerings in prior periods; directorships; for equity securities, market making and/or specialist role. Goldman Sachs usually makes a market in fixed income securities of issuers discussed in this report and usually deals as a principal in these securities.

The following are additional required disclosures: **Ownership and material conflicts of interest:** Goldman Sachs policy prohibits its analysts, professionals reporting to analysts and members of their households from owning securities of any company in the analyst's area of coverage.

**Analyst compensation:** Analysts are paid in part based on the profitability of Goldman Sachs, which includes investment banking revenues.

**Analyst as officer or director:** Goldman Sachs policy prohibits its analysts, persons reporting to analysts or members of their households from serving as an officer, director, advisory board member or employee of any company in the analyst's area of coverage. **Non-U.S. Analysts:** Non-U.S. analysts may not be associated persons of Goldman, Sachs & Co. and therefore may not be subject to NASD Rule 2711/NYSE Rules 472 restrictions on communications with subject company, public appearances and trading securities held by the analysts.

**Distribution of ratings:** See the distribution of ratings disclosure above. **Price chart:** See the price chart, with changes of ratings and price targets in prior periods, above, or, if electronic format or if with respect to multiple companies which are the subject of this report, on the Goldman Sachs website at <http://www.gs.com/research/hedge.html>.

### Additional disclosures required under the laws and regulations of jurisdictions other than the United States

The following disclosures are those required by the jurisdiction indicated, except to the extent already made above pursuant to United States laws and regulations. **Australia:** This research, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. **Brazil:** Disclosure information in relation to CVM Instruction 483 is available at

<http://www.gs.com/worldwide/brazil/area/gir/index.html>. Where applicable, the Brazil-registered analyst primarily responsible for the content of this research report, as defined in Article 16 of CVM Instruction 483, is the first author named at the beginning of this report, unless indicated otherwise at the end of the text. **Canada:** Goldman, Sachs & Co. has approved of, and agreed to take responsibility for, this research in Canada if and to the extent it relates to equity securities of Canadian issuers. Analysts may conduct site visits but are prohibited from accepting payment or reimbursement by the company of travel expenses for such visits. **Hong Kong:** Further information on the securities of covered companies referred to in this research may be obtained on request from Goldman Sachs (Asia) L.L.C. **India:** Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (India) Securities Private Limited; **Japan:** See below. **Korea:** Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (Asia) L.L.C., Seoul Branch. **Russia:**

Research reports distributed in the Russian Federation are not advertising as defined in the Russian legislation, but are information and analysis not having product promotion as their main purpose and do not provide appraisal within the meaning of the Russian legislation on appraisal activity. **Singapore:** Further information on the covered companies referred to in this research may be obtained from Goldman Sachs (Singapore) Pte. (Company Number: 198602165W). **Taiwan:** This material is for reference only and must not be reprinted without permission. Investors should carefully consider their own investment risk. Investment results are the responsibility of the individual investor. **United Kingdom:** Persons who would be categorized as retail clients in the United Kingdom, as such term is defined in the rules of the Financial Services Authority, should read this research in conjunction with prior Goldman Sachs research on the covered companies referred to herein and should refer to the risk warnings that have been sent to them by Goldman Sachs International. A copy of these risks warnings, and a glossary of certain financial terms used in this report, are available from Goldman Sachs International on request.

**European Union:** Disclosure information in relation to Article 4 (1) (d) and Article 6 (2) of the European Commission Directive 2003/126/EC is available at <http://www.gs.com/disclosures/europeanpolicy.html> which states the European Policy for Managing Conflicts of Interest in Connection with Investment Research.

**Japan:** Goldman Sachs Japan Co., Ltd. is a Financial Instrument Dealer under the Financial Instrument and Exchange Law, registered with the Kanto Financial Bureau (Registration No. 69), and is a member of Japan Securities Dealers Association (JSDA) and Financial Futures Association of Japan (FFAJ). Sales and purchase of equities are subject to commission pre-determined with clients plus consumption tax. See company-specific disclosures as to any applicable disclosures required by Japanese stock exchanges, the Japanese Securities Dealers Association or the Japanese Securities Finance Company.

**European Union:** Disclosure information in relation to Article 4 (1) (d) and Article 6 (2) of the European Commission Directive 2003/126/EC is available at <http://www.gs.com/disclosures/europeanpolicy.html> which states the European Policy for Managing Conflicts of Interest in Connection with Investment Research.

**Japan:** Goldman Sachs Japan Co., Ltd. is a Financial Instrument Dealer under the Financial Instrument and Exchange Law, registered with the Kanto Financial Bureau (Registration No. 69), and is a member of Japan Securities Dealers Association (JSDA) and Financial Futures Association of Japan (FFAJ). Sales and purchase of equities are subject to commission pre-determined with clients plus consumption tax. See company-specific disclosures as to any applicable disclosures required by Japanese stock exchanges, the Japanese Securities Dealers Association or the Japanese Securities Finance Company.

## Ratings, coverage groups and views and related definitions

**Buy (B), Neutral (N), Sell (S)** -Analysts recommend stocks as Buys or Sells for inclusion on various regional Investment Lists. Being assigned a Buy or Sell on an Investment List is determined by a stock's return potential relative to its coverage group as described below. Any stock not assigned as a Buy or a Sell on an Investment List is deemed Neutral. Each regional Investment Review Committee manages various regional Investment Lists to a global guideline of 25%-35% of stocks as Buy and 10%-15% of stocks as Sell; however, the distribution of Buys and Sells in any particular coverage group may vary as determined by the regional Investment Review Committee. Regional Conviction Buy and Sell lists represent investment recommendations focused on either the size of the potential return or the likelihood of the realization of the return.

**Return potential** represents the price differential between the current share price and the price target expected during the time horizon associated with the price target. Price targets are required for all covered stocks. The return potential, price target and associated time horizon are stated in each report adding or reiterating an Investment List membership.

**Coverage groups and views:** A list of all stocks in each coverage group is available by primary analyst, stock and coverage group at <http://www.gs.com/research/hedge.html>. The analyst assigns one of the following coverage views which represents the analyst's investment outlook on the coverage group relative to the group's historical fundamentals and/or valuation. **Attractive (A).** The investment outlook over the following 12 months is favorable relative to the coverage group's historical fundamentals and/or valuation. **Neutral (N).** The investment outlook over the following 12 months is neutral relative to the coverage group's historical fundamentals and/or valuation. **Cautious (C).** The investment outlook over the following 12 months is unfavorable relative to the coverage group's historical fundamentals and/or valuation.

**Not Rated (NR).** The investment rating and target price have been removed pursuant to Goldman Sachs policy when Goldman Sachs is acting in an advisory capacity in a merger or strategic transaction involving this company and in certain other circumstances. **Rating Suspended (RS).** Goldman Sachs Research has suspended the investment rating and price target for this stock, because there is not a sufficient fundamental basis for determining, or there are legal, regulatory or policy constraints around publishing, an investment rating or target. The previous investment rating and price target, if any, are no longer in effect for this stock and should not be relied upon. **Coverage Suspended (CS).** Goldman Sachs has suspended coverage of this company. **Not Covered (NC).** Goldman Sachs does not cover this company. **Not Available or Not Applicable (NA).** The information is not available for display or is not applicable. **Not Meaningful (NM).** The information is not meaningful and is therefore excluded.

## Global product; distributing entities

The Global Investment Research Division of Goldman Sachs produces and distributes research products for clients of Goldman Sachs, and pursuant to certain contractual arrangements, on a global basis. Analysts based in Goldman Sachs offices around the world produce equity research on industries and companies, and research on macroeconomics, currencies, commodities and portfolio strategy. This research is disseminated in Australia by Goldman Sachs Australia Pty Ltd (ABN 21 006 797 897); in Brazil by Goldman Sachs do Brasil Banco Múltiplo S.A.; in Canada by Goldman, Sachs & Co. regarding Canadian equities and by Goldman, Sachs & Co. (all other research); in Hong Kong by Goldman Sachs (Asia) L.L.C.; in India by Goldman Sachs (India) Securities Private Ltd.; in Japan by Goldman Sachs Japan Co., Ltd.; in the Republic of Korea by Goldman Sachs (Asia) L.L.C., Seoul Branch; in New Zealand by Goldman Sachs New Zealand Limited; in Russia by OOO Goldman Sachs; in Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 198602165W); and in the United States of America by Goldman, Sachs & Co. Goldman Sachs International has approved this research in connection with its distribution in the United Kingdom and European Union.

**European Union:** Goldman Sachs International, authorized and regulated by the Financial Services Authority, has approved this research in connection with its distribution in the European Union and United Kingdom; Goldman Sachs AG, regulated by the Bundesanstalt für Finanzdienstleistungsaufsicht, may also distribute research in Germany.

## General disclosures

This research is for our clients only. Other than disclosures relating to Goldman Sachs, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst's judgment.

Goldman Sachs conducts a global full-service, integrated investment banking, investment management, and brokerage business. We have investment banking and other business relationships with a substantial percentage of the companies covered by our Global Investment Research Division. Goldman, Sachs & Co., the United States broker dealer, is a member of SIPC (<http://www.sipc.org>).

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and our proprietary trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset management area, our proprietary trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

The analysts named in this report may have from time to time discussed with our clients, including Goldman Sachs salespersons and traders, or may discuss in this report, trading strategies that reference catalysts or events that may have a near-term impact on the market price of the equity securities discussed in this report, which impact may be directionally counter to the analysts' published price target expectations for such stocks. Any such trading strategies are distinct from and do not affect the analysts' fundamental equity rating for such stocks, which rating reflects a stock's return potential relative to its coverage group as described herein.

We and our affiliates, officers, directors, and employees, excluding equity and credit analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research.

This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Investors should review current options disclosure documents which are available from Goldman Sachs sales representatives or at <http://www.theocc.com/about/publications/character-risks.jsp>. Transactions cost may be significant in option strategies calling for multiple purchase and sales of options such as spreads. Supporting documentation will be supplied upon request.

All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Not all research content is redistributed to our clients or available to third-party aggregators, nor is Goldman Sachs responsible for the redistribution of our research by third party aggregators. For all research available on a particular stock, please contact your sales representative or go to <http://360.gs.com>.

Disclosure information is also available at <http://www.gs.com/research/hedge.html> or from Research Compliance, 200 West Street, New York, NY 10282.

**Copyright 2011 Goldman Sachs.**

**No part of this material may be (i) copied, photocopied or duplicated in any form by any means or (ii) redistributed without the prior written consent of The Goldman Sachs Group, Inc.**

